Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Genesys posts positive phase II cancer vaccine data
One-year survival was 88% and two-year survival was 76%, with a mean follow-up of approximately 24 months. These results compare favorably with historical data from multiple studies in
One-year survival was 88% and two-year survival was 76%, with a mean follow-up of approximately 24 months. These results compare favorably with historical data from multiple studies in
Building on successful data derived from its proprietary in vitro models of the disease, Synairgen is investigating a novel application of inhaled interferon-Beta (IFN-Beta) to reduce asthma exacerbations
Acute coronary syndromes (ACS) account for more than one million hospitalizations annually in the US. ACS occurs when an atherosclerotic plaque ruptures in a coronary artery, triggering the
The drug, which is a serotonin 4 (5-HT4) receptor agonist, was also well-tolerated in the trial. The company now expects to initiate a phase II dose-ranging trial in
It is the first and only non-avian derived hyaluronic acid indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy
The phase I trial with NGX424 will enroll approximately 90 healthy male volunteers at one center in the US, and will evaluate the local and systemic tolerability, safety
Eyetech stockholders will receive $15 per share in cash and 0.12275 of OSI shares for each share of Eyetech owned as of the closing date. OSI completed the
Orphan designation has been granted on the basis of Bronchitol’s potential to treat cystic fibrosis, a genetic disease which, for the patient, is characterized by recurring respiratory complications.
The approval was based on the results of the largest prospective, randomized and double-blind clinical trial ever conducted in diabetic patients with moderate to severe complicated foot infection.
SCH 503034 was shown to have potential in treating the disease both on its own and in combination with Peg-Intron (peginterferon alfa-2b). Hepatitis C virus (HCV) genotype 1